Overview

FRIENDS-01A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11

Status:
NOT_YET_RECRUITING

Trial end date:
2026-07-21

Target enrollment:

Participant gender:

Summary

FRIENDS-01A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11

Phase:

PHASE3

Details

Lead Sponsor:

The First Affiliated Hospital with Nanjing Medical University

Treatments:

Interleukin-11
oprelvekin